%0 Journal Article
%A Mynarek, Martin
%A von Hoff, Katja
%A Pietsch, Torsten
%A Ottensmeier, Holger
%A Warmuth-Metz, Monika
%A Bison, Brigitte
%A Pfister, Stefan
%A Korshunov, Andrey
%A Sharma, Tanvi
%A Jaeger, Natalie
%A Ryzhova, Marina
%A Zheludkova, Olga
%A Golanov, Andrey
%A Rushing, Elisabeth Jane
%A Hasselblatt, Martin
%A Koch, Arend
%A Schüller, Ulrich
%A von Deimling, Andreas
%A Sahm, Felix
%A Sill, Martin
%A Riemenschneider, Markus J.
%A Dohmen, Hildegard
%A Monoranu, Camelia Maria
%A Sommer, Clemens
%A Staszewski, Ori
%A Mawrin, Christian
%A Schittenhelm, Jens
%A Brück, Wolfgang
%A Filipski, Katharina
%A Hartmann, Christian
%A Meinhardt, Matthias
%A Pietschmann, Klaus
%A Haberler, Christine
%A Slavc, Irene
%A Gerber, Nicolas U.
%A Grotzer, Michael
%A Benesch, Martin
%A Schlegel, Paul Gerhardt
%A Deinlein, Frank
%A von Bueren, André O.
%A Friedrich, Carsten
%A Juhnke, Björn-Ole
%A Obrecht, Denise
%A Fleischhack, Gudrun
%A Kwiecien, Robert
%A Faldum, Andreas
%A Kortmann, Rolf Dieter
%A Kool, Marcel
%A Rutkowski, Stefan
%T Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort
%J Journal of clinical oncology
%V 38
%N 18
%@ 1527-7755
%C Alexandria, Va.
%I American Society of Clinical Oncology
%M DZNE-2020-01353
%P 2028 - 2040
%D 2020
%X PURPOSEThe HIT-2000-BIS4 trial aimed to avoid highly detrimental craniospinal irradiation (CSI) in children < 4 years of age with nonmetastatic medulloblastoma by systemic chemotherapy, intraventricular methotrexate, and risk-adapted local radiotherapy.PATIENTS AND METHODSFrom 2001-2011, 87 patients received systemic chemotherapy and intraventricular methotrexate. Until 2006, CSI was reserved for nonresponse or progression. After 2006, local radiotherapy was introduced for nonresponders or patients with classic medulloblastoma (CMB) or large-cell/anaplastic medulloblastoma (LCA). DNA methylation profiles of infantile sonic hedgehog-activated medulloblastoma (SHH-INF) were subdivided into iSHH-I and iSHH-II subtypes in the HIT-2000-BIS4 cohort and a validation cohort (n = 71) from the HIT group and Russia.RESULTSFive years after diagnosis, patients with desmoplastic medulloblastoma (DMB) or medulloblastoma with extensive nodularity (MBEN; n = 42) had 93
%K Cerebellar Neoplasms: drug therapy
%K Cerebellar Neoplasms: mortality
%K Cerebellar Neoplasms: radiotherapy
%K Child, Preschool
%K Cranial Irradiation: adverse effects
%K DNA Methylation
%K Female
%K Humans
%K Infant
%K Male
%K Medulloblastoma: drug therapy
%K Medulloblastoma: mortality
%K Medulloblastoma: radiotherapy
%K Methotrexate: administration & dosage
%K Neuropsychological Tests
%K Prospective Studies
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:32330099
%R 10.1200/JCO.19.03057
%U https://pub.dzne.de/record/153356